A5016057883- Sarcoma Diagnosis and Treatment
- Bone health and treatments
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Neuroblastoma Research and Treatments
- Bladder and Urothelial Cancer Treatments
- Radiopharmaceutical Chemistry and Applications
- Vascular Tumors and Angiosarcomas
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Cancer Cells and Metastasis
- Urinary and Genital Oncology Studies
- Medical Imaging and Pathology Studies
- Cancer Genomics and Diagnostics
- Cardiac tumors and thrombi
- Bone Metabolism and Diseases
- Renal and related cancers
- Cancer Immunotherapy and Biomarkers
- Multiple and Secondary Primary Cancers
- Venous Thromboembolism Diagnosis and Management
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- RNA Research and Splicing
- Neutropenia and Cancer Infections
Azienda Ospedaliera San Giovanni Addolorata
2021-2024
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2016-2022
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2022
Houston Methodist
2017
Carlo Forlanini Hospital
2010-2016
Azienda Ospedaliera San Camillo-Forlanini
2015-2016
IRCCS San Camillo Hospital
2010
BACKGROUND Gemcitabine plus cisplatin (GC) has been adopted as a neoadjuvant regimen for muscle‐invasive bladder cancer despite the lack of Level I evidence in this setting. METHODS Data were collected using an electronic data‐capture platform from 28 international centers. Eligible patients had clinical T‐classification 2 (cT2) through cT4aN0M0 urothelial and received GC or methotrexate, vinblastine, doxorubicin, (MVAC) before undergoing cystectomy. Logistic regression was used to compute...
Bone metastasis is a complex process that needs to be better understood in order help clinicians prevent and treat it. Xenografts using patient-derived material (PDX) rather than cancer cell lines are novel approach guarantees more clinically realistic results. A primary culture of bone derived from 67-year-old patient with breast was cultured then injected into zebrafish (ZF) embryos study its metastatic potential. In vivo behavior results gene expression analyses the were compared those...
Abstract Background Soft tissue sarcomas (STS) are a rare group of solid neoplasm including among others liposarcoma, leiomyosarcoma (L-sarcoma) and undifferentiated pleomorphic sarcoma (UPS) entities. The current first-line treatment is represented by anthracycline based- regimens, second-line may include trabectedin. Currently the activity trabectedin its mechanism action not completely elucidated. Methods Taking advantages our 3D patient-derived primary culture translational model we...
Giant cell tumor of bone (GCTB) and desmoplastic fibroma (DF) are sarcomas with intermediate malignant behavior unpredictable prognosis. These locally aggressive neoplasms exhibit a predilection for the long or mandible young adults, causing severe resorption. In particular, stromal cells these lesions responsible recruiting multinucleated giant which ultimately lead to disruption. this regard, underlying pathological mechanism osteoclastogenesis processes in GCTB DF is still poorly...
NTRK (neurotrophic tyrosine receptor kinase)-rearranged spindle cell neoplasms are a new group of tumors included in the 5th edition World Health Organization (WHO) classification soft Tissue and Bone Sarcomas. These characterized by gene fusions show wide spectrum histologies clinical behavior. Several targeted therapies have recently been approved for harboring fusions, including STS.A 26-year-old male with advanced, pretreated rearranged neoplasm liver, lung bone metastases was treated...
Myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) can be considered as a spectrum of the same disease entity, representing one most common adult soft tissue (STS) extremities. While MFS is rarely metastasizing, it shows an extremely high rate multiple frequent local recurrences (50–60% cases). On other hand, UPS aggressive prone to distant recurrence, which correlated poor prognosis. Differential diagnosis challenging due their heterogeneous morphology, with remaining...
Immunotherapy has emerged as promising treatment in sarcomas, but the high variability terms of histology, clinical behavior and response to treatments determines a particular challenge for its role these neoplasms. Tumor immune microenvironment (TiME) sarcomas reflects heterogeneity tumors originating from mesenchymal cells encompassing more than 100 histologies. Advances understanding complexity TiME have led an improvement immunotherapeutic responsiveness that at first showed...
Bone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs) have dramatically changed the therapeutic landscape of NSCLC, little information is available on BMs from NSCLC treated ICIs alone or association bone-targeted therapy (BTT) such as zoledronate denosumab.From 2014 to 2020, 111 142 secondary extrapolated prospective multicenter Italian BM Database were eligible for analysis. Information blood...
Neuroendocrine Carcinomas (NECs) prognosis is poor.No standard second-line therapy currently recognized after failure of platinum-based first-line treatment. FOLFIRI and CAPTEM regimens have shown promising activity in preliminary studies. We aimed to evaluate these metastatic NEC patients.
Undifferentiated pleomorphic sarcoma (UPS) is an aggressive mesenchymal neoplasm with no specific line of differentiation. Eribulin, a novel synthetic microtubule inhibitor, has shown anticancer activity in several tumors, including soft tissue sarcomas (STS). We investigated the molecular biology UPS, and mechanisms action this innovative microtubule-depolymerizing drug. A primary culture from patient UPS was established characterized terms gene expression. The eribulin also compared that...
Adult rhabdomyosarcoma (RMS) represents an uncommon entity with incidence of less than 3% all soft tissue sarcomas (STS). Consequently, the natural history and clinical management this disease are infrequently reported. In order to fill gap, we investigated molecular biology adult RMS case series. The expression epithelial mesenchymal transition-related gene chemoresistance-related panels were evaluated. Moreover, taking advantage our STS translational model combining patient-derived primary...
Background: Myxofibrosarcoma (MFS), formerly considered as a myxoid variant of malignant fibrous histiocytoma, is the most common sarcoma extremities in adults and characterized by high frequency local recurrence. The clinical behavior MFS unpredictable efficacy chemotherapy still not well documented. Furthermore, given relatively recent recognition distinct pathologic entity its cellular molecular biology has been extensively studied patient-derived preclinical models. We examined treatment...
Metastatic bone disease has a major impact on morbidity of breast cancer (BC) patients. Alterations in mTOR signaling are involved both progression and osteoclast differentiation. The purpose this study was to assess the role inhibitor Everolimus (Eve) osteoclastogenesis induced by triple negative BC cells. To aim, we developed an vitro human model from peripheral blood monocytes co-cultured with SCP2 hormonal receptor positive MCF7 cell lines. Osteoclastogenesis evaluated TRAP staining,...
Although bone metastases represent a major challenge in the natural history of breast cancer (BC), complex interactions involved have hindered development robust vitro models. The aim this work is preclinical model and stromal cells to mimic microenvironment. We studied effects on osteoclastogenesis BC Mesenchymal stem (MSC) cultured alone or combination. also analyzed: (a) whether blockade Epithelial Growth Factor Receptor (EGFR) pathway modified their influence monocytes towards...